Vpriv velaglucerase alfa regulatory update

The European Commission approved an MAA from Shire for Vpriv velaglucerase alfa to treat Type I Gaucher's disease. The glucocerebrosidase enzyme replacement therapy, which has Orphan Drug status in t...